Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of rituximab with chemotherapy for children and teenagers who have B cell lymphoma (Inter-B-NHL Ritux 2010)
This trial looked at a drug called rituximab alongside chemotherapy for B cell lymphoma in children and young people up to the age of 18.
The trial was supported by Cancer Research UK. It was open for people to join between 2011 and 2017. The team published the results in 2020.
More about this trial
B cell lymphoma is a type of non Hodgkin lymphoma. When this trial was done, doctors usually used chemotherapy to treat it. Researchers wanted to find out if having rituximab as well would improve treatment.
We already knew from research that this combination of treatment was useful for adults with certain types of B cell lymphoma. Researchers wanted to find out if this was the case for children.
This trial was for children with types of high grade B cell lymphoma such as Burkitt’s lymphoma and diffuse large B cell lymphoma.
The main aims of the trial were to find out:
- if adding rituximab to chemotherapy improves treatment for B cell lymphoma in children and young people
- more about any long term risks of rituximab for these patients
Summary of results
The results showed that rituximab and chemotherapy could be a useful treatment for children and young people with B cell lymphoma.
This trial was for children and young people between 6 months and 18 years old, with B cell lymphoma. They hadn’t had treatment before.
Some people taking part had chemotherapy as usual. And some people had chemotherapy and rituximab.
A total of 362 children joined this trial. The research team were able to analyse the results for 328 of them.
They were put into 1 of 2 treatment groups at random:
- 164 had chemotherapy
- 164 had chemotherapy and rituximab
The research team looked at how many people’s lymphoma had not gone away or had come back again, about 3 years after treatment. They found it was:
- 23 people (14%) who had chemotherapy
- 3 people (2%) who had chemotherapy and rituximab
They also looked at how many people were living, and found it was:
- 144 people (88%) who had chemotherapy
- 156 people (95%) who had chemotherapy and rituximab
Most people who took part had at least 1 side effect. Some of them were mild or didn’t last long. But some people in each group had side effects that were more serious:
- more than 3 out of 10 people (33%) who had chemotherapy
- nearly 4 out of 10 people (38%) who had chemotherapy and rituximab
The most common more serious side effects were:
- a high temperature and low white blood cells (febrile neutropenia)
- an infection
- a sore mouth (mucositis)
Some people in each group had low levels of a protein called immunoglobulin G (IgG). Immunoglobulin G is part of our immune system. It helps us fight bacteria and viruses.
The trial team looked at how many people had low IgG levels a year after treatment. It was:
- more than 2 out of 10 people (25%) who had chemotherapy
- more than 5 out of 10 people (56%) who had chemotherapy and rituximab
The research team concluded that rituximab and chemotherapy helped children with B cell lymphoma live longer. But it did cause more side effects.
They suggest that children and teenagers who have B cell lymphoma should have this combination of treatment.
They also found a way for research teams around the world to work together and run trials for children with rare cancers.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Amos Burke
Alex Hulme Foundation
Cancer Research UK
Syneos Health (formerly InVentiv Health)
University of Birmingham
This is Cancer Research UK trial number CRUK/11/038.